Last reviewed · How we verify

KetoNaph

Bausch & Lomb Incorporated · Phase 3 active Small molecule

KetoNaph is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye.

KetoNaph is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye. Used for Postoperative inflammation and pain following cataract surgery, Postoperative inflammation and pain following refractive surgery.

At a glance

Generic nameKetoNaph
SponsorBausch & Lomb Incorporated
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCOX-1, COX-2
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

KetoNaph works by blocking COX-1 and COX-2 enzymes in ocular tissues, thereby reducing the production of prostaglandins that mediate inflammation, pain, and other inflammatory responses. As a topical ophthalmic formulation, it delivers the active ingredient directly to the eye to manage postoperative inflammation and pain following cataract surgery and other ocular procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: